Analyst Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.

Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the ...

Pfizer reported an earnings beat Tuesday morning and raised its full-year outlook, seeing strength in sales of its Covid ...

NEW YORK — A boost from Covid-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher ...

Pfizer’s third-quarter revenue and adjusted profit exceeded expectations, driven by strong sales of its Covid vaccine and ...

We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.

Pfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.

Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. See why I think that 2025 will not be a strong year for PFE stock.

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

The pharma firm saw sales jump 31% in the period, mainly due to continuing demand for its COVID-19 treatment, Paxlovid. The ...

Pfizer CEO Albert Bourla, under pressure from activist hedge ... after it reported a higher-than-expected profit due to ...

Pfizer reported higher-than-expected profits driven by strong Paxlovid sales, offsetting a decline in COVID vaccine sales.